Merck Terminates Odanacatib Trial Early on Positive Results

Some investors were puzzled when shares of Quest Diagnostics Inc. surged nearly 5 percent Thursday morning for apparently no reason. They could hardly be blamed for not knowing that Madison, N.J.-based Quest is entitled to a rather large payday upon commercialization of Merck & Co. Inc.'s odanacatib, which just blasted through its Phase III study goals upon interim analysis.